Targeted therapies in breast cancer /:
The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of brea...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford ; New York :
Oxford University Press,
©2011.
|
| Schriftenreihe: | Oxford American pocket notes.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th. |
| Beschreibung: | 1 online resource (54 pages) : illustrations |
| Bibliographie: | Includes bibliographical references. |
| ISBN: | 9780199749751 0199749752 1280699094 9781280699092 9786613676061 6613676063 |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn795706882 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 120618s2011 enka obf 000 0 eng d | ||
| 010 | |z 2012419417 | ||
| 040 | |a N$T |b eng |e pn |c N$T |d E7B |d OHS |d YDXCP |d OCLCQ |d OCLCF |d OCLCO |d EBLCP |d IDEBK |d OCL |d OCLCQ |d OCLCO |d OCLCQ |d AGLDB |d OCLCQ |d OCLCO |d OCLCA |d UUM |d VNS |d VTS |d STF |d OCLCQ |d DKC |d OCLCO |d OCLCQ |d M8D |d OCLCO |d OCLCQ |d OCLCA |d VLY |d AJS |d OCLCO |d OCLCQ |d OCLCO |d INARC |d OCLCQ |d OCLCL |d OCLCQ | ||
| 015 | |a GBB052349 |2 bnb | ||
| 016 | 7 | |a 015534897 |2 Uk | |
| 019 | |a 796384634 |a 821643742 |a 1053886424 |a 1162207755 |a 1412548695 | ||
| 020 | |a 9780199749751 |q (electronic bk.) | ||
| 020 | |a 0199749752 |q (electronic bk.) | ||
| 020 | |a 1280699094 | ||
| 020 | |a 9781280699092 | ||
| 020 | |z 9780199735679 | ||
| 020 | |z 0199735670 | ||
| 020 | |a 9786613676061 | ||
| 020 | |a 6613676063 | ||
| 035 | |a (OCoLC)795706882 |z (OCoLC)796384634 |z (OCoLC)821643742 |z (OCoLC)1053886424 |z (OCoLC)1162207755 |z (OCoLC)1412548695 | ||
| 050 | 4 | |a RC280.B8 |b B87 2011eb | |
| 060 | 4 | |a WP 900 | |
| 072 | 7 | |a HEA |x 039030 |2 bisacsh | |
| 072 | 7 | |a MED |x 062000 |2 bisacsh | |
| 082 | 7 | |a 616.99449061 |2 22 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Burstein, Harold J. | |
| 245 | 1 | 0 | |a Targeted therapies in breast cancer / |c Harold J. Burstein. |
| 260 | |a Oxford ; |a New York : |b Oxford University Press, |c ©2011. | ||
| 300 | |a 1 online resource (54 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Oxford American pocket notes | |
| 504 | |a Includes bibliographical references. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References. | |
| 520 | |a The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Breast |x Cancer |x Treatment |v Handbooks, manuals, etc. | |
| 650 | 0 | |a Drug targeting |v Handbooks, manuals, etc. | |
| 650 | 2 | |a Drug Delivery Systems | |
| 650 | 2 | |a Breast Neoplasms |x drug therapy | |
| 650 | 6 | |a Sein |x Cancer |x Traitement |v Guides, manuels, etc. | |
| 650 | 6 | |a Médicaments |x Ciblage |v Guides, manuels, etc. | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x Cancer. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Oncology. |2 bisacsh | |
| 650 | 7 | |a Breast |x Cancer |x Treatment |2 fast | |
| 650 | 7 | |a Drug targeting |2 fast | |
| 655 | 7 | |a Handbooks and manuals |2 fast | |
| 776 | 0 | 8 | |i Print version: |a Burstein, Harold J. |t Targeted therapies in breast cancer. |d Oxford ; New York : Oxford University Press, ©2011 |z 9780199735679 |w (DLC) 2012419417 |w (OCoLC)619903409 |
| 830 | 0 | |a Oxford American pocket notes. |0 http://id.loc.gov/authorities/names/no2010038979 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=461408 |3 Volltext |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL943380 | ||
| 938 | |a ebrary |b EBRY |n ebr10569217 | ||
| 938 | |a EBSCOhost |b EBSC |n 461408 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 367606 | ||
| 938 | |a YBP Library Services |b YANK |n 8578561 | ||
| 938 | |a Internet Archive |b INAR |n targetedtherapie0000burs | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn795706882 |
|---|---|
| _version_ | 1816881798771113984 |
| adam_text | |
| any_adam_object | |
| author | Burstein, Harold J. |
| author_facet | Burstein, Harold J. |
| author_role | |
| author_sort | Burstein, Harold J. |
| author_variant | h j b hj hjb |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RC280 |
| callnumber-raw | RC280.B8 B87 2011eb |
| callnumber-search | RC280.B8 B87 2011eb |
| callnumber-sort | RC 3280 B8 B87 42011EB |
| callnumber-subject | RC - Internal Medicine |
| collection | ZDB-4-EBA |
| contents | Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References. |
| ctrlnum | (OCoLC)795706882 |
| dewey-full | 616.99449061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99449061 |
| dewey-search | 616.99449061 |
| dewey-sort | 3616.99449061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04278cam a2200745 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn795706882</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">120618s2011 enka obf 000 0 eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="z"> 2012419417</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OHS</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">EBLCP</subfield><subfield code="d">IDEBK</subfield><subfield code="d">OCL</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UUM</subfield><subfield code="d">VNS</subfield><subfield code="d">VTS</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">VLY</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">INARC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCL</subfield><subfield code="d">OCLCQ</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBB052349</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">015534897</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">796384634</subfield><subfield code="a">821643742</subfield><subfield code="a">1053886424</subfield><subfield code="a">1162207755</subfield><subfield code="a">1412548695</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780199749751</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0199749752</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1280699094</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781280699092</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780199735679</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0199735670</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9786613676061</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">6613676063</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)795706882</subfield><subfield code="z">(OCoLC)796384634</subfield><subfield code="z">(OCoLC)821643742</subfield><subfield code="z">(OCoLC)1053886424</subfield><subfield code="z">(OCoLC)1162207755</subfield><subfield code="z">(OCoLC)1412548695</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC280.B8</subfield><subfield code="b">B87 2011eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">WP 900</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">HEA</subfield><subfield code="x">039030</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">062000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">616.99449061</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Burstein, Harold J.</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted therapies in breast cancer /</subfield><subfield code="c">Harold J. Burstein.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford ;</subfield><subfield code="a">New York :</subfield><subfield code="b">Oxford University Press,</subfield><subfield code="c">©2011.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (54 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Oxford American pocket notes</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Breast</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drug targeting</subfield><subfield code="v">Handbooks, manuals, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Delivery Systems</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Breast Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Sein</subfield><subfield code="x">Cancer</subfield><subfield code="x">Traitement</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Ciblage</subfield><subfield code="v">Guides, manuels, etc.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">HEALTH & FITNESS</subfield><subfield code="x">Diseases</subfield><subfield code="x">Cancer.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Oncology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Breast</subfield><subfield code="x">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug targeting</subfield><subfield code="2">fast</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Handbooks and manuals</subfield><subfield code="2">fast</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Burstein, Harold J.</subfield><subfield code="t">Targeted therapies in breast cancer.</subfield><subfield code="d">Oxford ; New York : Oxford University Press, ©2011</subfield><subfield code="z">9780199735679</subfield><subfield code="w">(DLC) 2012419417</subfield><subfield code="w">(OCoLC)619903409</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Oxford American pocket notes.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2010038979</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=461408</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBL - Ebook Library</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL943380</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10569217</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">461408</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">367606</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">8578561</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Internet Archive</subfield><subfield code="b">INAR</subfield><subfield code="n">targetedtherapie0000burs</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| genre | Handbooks and manuals fast |
| genre_facet | Handbooks and manuals |
| id | ZDB-4-EBA-ocn795706882 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:18:27Z |
| institution | BVB |
| isbn | 9780199749751 0199749752 1280699094 9781280699092 9786613676061 6613676063 |
| language | English |
| oclc_num | 795706882 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (54 pages) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2011 |
| publishDateSearch | 2011 |
| publishDateSort | 2011 |
| publisher | Oxford University Press, |
| record_format | marc |
| series | Oxford American pocket notes. |
| series2 | Oxford American pocket notes |
| spelling | Burstein, Harold J. Targeted therapies in breast cancer / Harold J. Burstein. Oxford ; New York : Oxford University Press, ©2011. 1 online resource (54 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Oxford American pocket notes Includes bibliographical references. Print version record. Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References. The development of monoclonal antibodies and other inhibitors of specific molecules, fully utilizing the insights learned from molecular techniques such as comparative microarrays and protein expression patterns, has led to the development and FDA approval of several agents for the treatment of breast cancer, such as trastuzamab (Herceptin, targeting HER-2 positive tumors) and lapatinib (Tykerb, targeting tumors with mutated/overexpressed EGFR 1 and 2). Other agents specifically targeting the estrogen receptor, the aromatose pathway and microtubule dynamics, fulvestrant (Faslodex, targeting th. English. Breast Cancer Treatment Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Drug Delivery Systems Breast Neoplasms drug therapy Sein Cancer Traitement Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Breast Cancer Treatment fast Drug targeting fast Handbooks and manuals fast Print version: Burstein, Harold J. Targeted therapies in breast cancer. Oxford ; New York : Oxford University Press, ©2011 9780199735679 (DLC) 2012419417 (OCoLC)619903409 Oxford American pocket notes. http://id.loc.gov/authorities/names/no2010038979 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=461408 Volltext |
| spellingShingle | Burstein, Harold J. Targeted therapies in breast cancer / Oxford American pocket notes. Cover; Table of Contents; Introduction; Antiestrogen Therapies; Aromatase Inhibitors (AI's); Selective Estrogen Receptor Modulators (SERM's) and Estrogen-Receptor Downregulators (ERD's); Chemotherapeutic Agents-Microtubule Targeting Agents; Taxanes; Ixabepilone; Eribulin Mesylate; HER2 Directed Therapies for Metastatic Breast Cancer; Trastuzumab; Trastuzumab-Refactory Breast Cancer; Investigational Agents; HER2 Directed Therapy for Early Stage Breast Cancer; Angiogenesis Inhibitors in Breast Cancer; Bevacizumab; VEGFR Inhibitors; PARP Inhibitors; Emerging Areas; References. Breast Cancer Treatment Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Drug Delivery Systems Breast Neoplasms drug therapy Sein Cancer Traitement Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Breast Cancer Treatment fast Drug targeting fast |
| title | Targeted therapies in breast cancer / |
| title_auth | Targeted therapies in breast cancer / |
| title_exact_search | Targeted therapies in breast cancer / |
| title_full | Targeted therapies in breast cancer / Harold J. Burstein. |
| title_fullStr | Targeted therapies in breast cancer / Harold J. Burstein. |
| title_full_unstemmed | Targeted therapies in breast cancer / Harold J. Burstein. |
| title_short | Targeted therapies in breast cancer / |
| title_sort | targeted therapies in breast cancer |
| topic | Breast Cancer Treatment Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Drug Delivery Systems Breast Neoplasms drug therapy Sein Cancer Traitement Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. HEALTH & FITNESS Diseases Cancer. bisacsh MEDICAL Oncology. bisacsh Breast Cancer Treatment fast Drug targeting fast |
| topic_facet | Breast Cancer Treatment Handbooks, manuals, etc. Drug targeting Handbooks, manuals, etc. Drug Delivery Systems Breast Neoplasms drug therapy Sein Cancer Traitement Guides, manuels, etc. Médicaments Ciblage Guides, manuels, etc. HEALTH & FITNESS Diseases Cancer. MEDICAL Oncology. Breast Cancer Treatment Drug targeting Handbooks and manuals |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=461408 |
| work_keys_str_mv | AT bursteinharoldj targetedtherapiesinbreastcancer |